Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5176354
Max Phase: Preclinical
Molecular Formula: C213H295N47O57S7
Molecular Weight: 4650.44
Associated Items:
ID: ALA5176354
Max Phase: Preclinical
Molecular Formula: C213H295N47O57S7
Molecular Weight: 4650.44
Associated Items:
Canonical SMILES: CCCC[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H]2CSCCC(=O)N3CN(CN(C3)C(=O)CCSC[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)(C)C)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](CCCCNC(=O)CCc3cn(CCOCCOCCOCCOCCOCCC(=O)N[C@H]4CSCCC(=O)N5CN6CN(C5)C(=O)CCSC[C@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](Cc5cccc7ccccc57)NC(=O)[C@@H]5CCCN5C4=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCNC(=N)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc4c[nH]c5ccccc45)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N4CCC[C@H]4C(=O)N4C[C@H](O)C[C@H]4C(=O)N[C@@H](Cc4c[nH]c5ccccc45)C(=O)N[C@H](C(N)=O)CSCCC6=O)nn3)C(=O)N3CCC[C@H]3C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N2)C(=O)CCSC[C@@H](C(N)=O)NC1=O
Standard InChI: InChI=1S/C213H295N47O57S7/c1-9-10-38-141-186(287)241-157(182(214)283)110-319-89-64-171(269)248-116-250-120-251(117-248)175(273)68-93-323-114-161(200(301)231-147(95-125-30-12-11-13-31-125)189(290)222-122(2)184(285)229-146(58-61-178(277)278)207(308)256-73-26-45-165(256)203(304)235-148(190(291)226-141)96-126-48-53-133(264)54-49-126)243-191(292)149(97-127-50-55-134(265)56-51-127)236-202(303)164-44-25-72-255(164)206(307)145(230-187(288)143(57-60-177(275)276)228-201(302)163-43-27-74-257(163)208(309)155(104-213(5,6)7)239-198(299)159(223-124(4)263)112-321-91-66-173(250)271)42-21-22-70-218-169(267)59-52-132-107-254(247-246-132)77-79-314-81-83-316-85-87-317-86-84-315-82-80-313-78-62-170(268)224-162-115-324-94-69-176(274)253-119-249-118-252(121-253)174(272)67-92-322-113-160(244-196(297)154(103-180(281)282)234-192(293)150(237-204(305)166-46-28-75-258(166)209(162)310)98-129-34-24-33-128-32-14-15-35-136(128)129)199(300)227-144(63-88-318-8)188(289)225-142(41-20-23-71-219-212(216)217)185(286)233-153(102-179(279)280)195(296)232-151(99-130-105-220-139-39-18-16-36-137(130)139)193(294)240-156(109-261)197(298)245-181(123(3)262)211(312)259-76-29-47-167(259)210(311)260-108-135(266)101-168(260)205(306)238-152(100-131-106-221-140-40-19-17-37-138(131)140)194(295)242-158(183(215)284)111-320-90-65-172(249)270/h11-19,24,30-37,39-40,48-51,53-56,105-107,122-123,135,141-168,181,220-221,261-262,264-266H,9-10,20-23,25-29,38,41-47,52,57-104,108-121H2,1-8H3,(H2,214,283)(H2,215,284)(H,218,267)(H,222,290)(H,223,263)(H,224,268)(H,225,289)(H,226,291)(H,227,300)(H,228,302)(H,229,285)(H,230,288)(H,231,301)(H,232,296)(H,233,286)(H,234,293)(H,235,304)(H,236,303)(H,237,305)(H,238,306)(H,239,299)(H,240,294)(H,241,287)(H,242,295)(H,243,292)(H,244,297)(H,245,298)(H,275,276)(H,277,278)(H,279,280)(H,281,282)(H4,216,217,219)/t122-,123+,135+,141-,142-,143-,144-,145+,146-,147-,148-,149-,150-,151-,152-,153-,154+,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,181-/m0/s1
Standard InChI Key: JSHLYRKVAIQTQB-QPMFCGJUSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 4650.44 | Molecular Weight (Monoisotopic): 4646.9675 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Upadhyaya P, Kristensson J, Lahdenranta J, Repash E, Ma J, Kublin J, Mudd GE, Luus L, Jeffrey P, Hurov K, McDonnell K, Keen N.. (2022) Discovery and Optimization of a Synthetic Class of Nectin-4-Targeted CD137 Agonists for Immuno-oncology., 65 (14.0): [PMID:35819182] [10.1021/acs.jmedchem.2c00505] |
Source(1):